The diversity of 68Ga-Based imaging agents

Recent Results in Cancer Research

Volumn 194, Issue , 2013, Pages 101-131

  Velikyan, Irina ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Positron emission tomography; Radiochemistry

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GALLIUM 68; MESSENGER RNA; SOMATOSTATIN RECEPTOR; TRACER; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ARTICLE; BINDING AFFINITY; CHEMICAL STRUCTURE; DRUG HALF LIFE; GENE EXPRESSION REGULATION; GENE SEQUENCE; HUMAN; IMAGE QUALITY; ISOTOPE LABELING; MOLECULAR IMAGING; MOLECULAR WEIGHT; NONHUMAN; PERSONALIZED MEDICINE; POINT MUTATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE DISTRIBUTION; RADIOACTIVITY; RADIOCHEMISTRY; RADIOISOTOPE DIAGNOSIS; RECEPTOR BINDING;

EID: 84867037763     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-27994-2_7     Document Type: Article

References (239)

1. Ahlgren S, Tolmachev V (2010) Radionuclide molecular imaging using affibody molecules. Curr Pharm Biotechnol 11(6):581-589
2. Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D, Nanni C, Rizzello A, Franchi R, Fanti S (2008) Comparison between 68 Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging 35(8):1431
3. Ambrosini V, Zompatori M, De Luca F, Antonia DE, Allegri V, Nanni C, Malvi D, Tonveronachi E, Fasano L, Fabbri M, Fanti S (2010a) 68 Ga-DOTANOC PET/CT allows somatostatin receptor imaging in idiopathic pulmonary fibrosis: Preliminary results. J Nucl Med 51(12):1950-1955
4. Ambrosini V, Nanni C, Zompatori M, Campana D, Tomassetti P, Castellucci P, Allegri V, Rubello D, Montini G, Franchi R, Fanti S (2010b) Ga-68-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 37(4):722-727
5. Ambrosini V, Campana D, Allegri V, Opocher G, Fanti S (2011) 68 Ga-DOTA-NOC PET/CT detects somatostatin receptors expression in von Hippel-Lindau cerebellar disease. Clin Nucl Med 36(1):64-65
6. Antunes P, Ginj M, Walter MA, Chen J, Reubi JC, Maecke HR (2007) Influence of different spacers on the biological profile of a DOTA-somatostatin analogue. Bioconjugate Chem 18(1):84-92 (Pubitemid 46145997)
7. Asti M, De Pietri G, Fraternali A, Grassi E, Sghedoni R, Floroni F, Roesch F, Versari A, Salvo D (2008) Validation of Ge-68/Ga-68 generator processing by chemical purification for routine clinical application of Ga-68-DOTATOC. Nucl Med Biol 35(6):721-724
8. Autio A, Ujula T, Luoto P, Salomaki S, Jalkanen S, Roivainen A (2010) PET imaging of inflammation and adenocarcinoma xenografts using vascular adhesion protein 1 targeting peptide 68 Ga-DOTAVAP-P1: Comparison with 18F-FDG. Eur J Nucl Med Mol Imaging 37(10):1918-1925
9. Backer MV, Levashova Z, Patel V, Jehning BT, Claffey K, Blankenberg FG, Backer JM (2007) Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGFbased probes. Nat Med 13(4):504-509 (Pubitemid 46559824)
10. Backer MV, Levashova Z, Levenson R, Blankenberg FG, Backer JM (2008) Cysteine-containing fusion tag for site-specific conjugation of therapeutic and imaging agents to targeting proteins. Methods Mol Biol 494:275-294.
11. Clifton, NJ Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, Kvols LK, Krenning EP, Jamar F, Pauwels S (2005) Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: Relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 46(Suppl 1):99S-106S
12. Baum RP, Prasad V, Frischknecht M, Maecke H, Reubi J (2007) Bombesin receptor imaging in various tumors: First results of Ga-68 AMBA PET/CT. Eur J Nucl Med Mol Imaging 34:S193-S193
13. Baum RP, Prasad V, Hommann M, Horsch D (2008) Receptor PET/CT imaging of neuroendocrine tumors. Recent Results Cancer Res 170:225-242
14. Baum RP, Prasad V, Muller D, Schuchardt C, Orlova A, Wennborg A, Tolmachev V, Feldwisch J (2010) Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68 Ga-labeled affibody molecules. J Nucl Med 51(6):892-897
15. Bauwens M, Chekol R, Vanbilloen H, Bormans G, Verbruggen A (2010) Optimal buffer choice of the radiosynthesis of Ga-68-Dotatoc for clinical application. Nucl Med Commun 31(8):753-758
16. Behr TM, Behe M, Becker W (1999) Diagnostic applications of radiolabeled peptides in nuclear endocrinology. Q J Nucl Med 43(3):268-280 (Pubitemid 29500583)
17. Beller GA, Alton WJ, Cochavi S, Hnatowich D, Brownell GL (1979) Assessment of regional myocardial perfusion by positron emission tomography after intra-coronary administration of Ga-68 labeled albumin microspheres. J Comput Assist Tomogr 3(4):447-452 (Pubitemid 9218359)
18. Bergstrom M, Grahnen A, Langstrom B (2003) Positron emission tomography microdosing: A new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol 59(5-6):357-366 (Pubitemid 37214939)
19. Bergstrom SK, Edenwall N, Laven M, Velikyan I, Langstrom B, Markides KE (2005) Polyamine deactivation of integrated poly(dimethylsiloxane) structures investigated by radionuclide imaging and capillary electrophoresis experiments. Anal Chem 77(3):938-942 (Pubitemid 40194159)
20. Blom E, Langstrom B, Velikyan I (2009) (68)Ga-labeling of biotin analogues and their characterization. Bioconjug Chem 20:1146-1151
21. Blom E, Velikyan I, Monazzam A, Razifar P, Nair M, Razifar P, Vanderheyden J-L, Krivoshein AV, Backer M, Backer J, Långström B (2011) Synthesis and characterization of scVEGFPEG-[Ga]NOTA and scVEGF-PEG-[68 Ga]DOTA PET tracers. J Labelled Compounds Radiopharm: N/a-n/a
22. Boerman OC, van Schaijk FG, Oyen WJG, Corstens FHM (2003) Pretargeted radioimmunotherapy of cancer: Progress step by step. J Nucl Med 44(3):400-411
23. Borges JB, Velikyan I, Långström B, Sörensen J, Ulin J, Maripuu E, Sandström M, Widström C, Hedenstierna G (2011) Ventilation distribution studies comparing Technegas and Gallgas using 68 GaCl3 as the label. J Nucl Med 52:206-209
24. Boss A, Bisdas S, Kolb A, Hofmann M, Ernemann U, Claussen CD, Pfannenberg C, Pichler BJ, Reimold M, Stegger L (2010) Hybrid PET/MRI of intracranial masses: Initial experiences and comparison to PET/CT. J Nucl Med 51(8):1198-1205
25. Brom M, Oyen WJ, Joosten L, Gotthardt M, Boerman OC (2010) 68 Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET. Eur J Nucl Med Mol Imaging 37(7):1345-1355
26. Cagnolini A, Chen J, Ramos K, Skedzielewski TM, Lantry LE, Nunn AD, Swenson RE, Linder KE (2010) Automated synthesis, characterization and biological evaluation of [(68)Ga]Ga-AMBA, and the synthesis and characterization of (nat)Ga-AMBA and [(67)Ga]Ga-AMBA. Appl Radiat Isot 68(12):2285-2292
27. Campana D, Ambrosini V, Pezzilli R, Fanti S, Labate AMM, Santini D, Ceccarelli C, Nori F, Franchi R, Corinaldesi R, Tomassetti P (2010) Standardized uptake values of 68 Ga-DOTANOC PET: A promising prognostic tool in neuroendocrine tumors. J Nucl Med 51(3):353-359
28. Cantorias MV, Figueroa SD, Quinn TP, Lever JR, Hoffman TJ, Watkinson LD, Carmack TL, Cutler CS (2009) Development of high-specific-activity Ga-68-labeled DOTA-rheniumcyclized alpha-MSH peptide analog to target MC1 receptors overexpressed by melanoma tumors. Nucl Med Biol 36(5):505-513
29. Carlsson J, Forssell-Aronsson E, Glimelius B, Mattsson S (2002) Therapy with radiopharmaceuticals. Acta Oncol 41(7-8):623-628 (Pubitemid 36106205)
30. Carlsson J, Forssell Aronsson E, Hietala SO, Stigbrand T, Tennvall J (2003) Tumour therapy with radionuclides: Assessment of progress and problems. Radiother Oncol 66(2):107-117 (Pubitemid 36321806)
31. Cescato R, Erchegyi J, Waser B, Piccand V, Maecke HR, Rivier JE, Reubi JC (2008) Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting. J Med Chem 51(13):4030-4037 (Pubitemid 351956530)
32. Chang C-H, Sharkey RM, Rossi EA, Karacay H, McBride W, Hansen HJ, Chatal J-F, Barbet J, Goldenberg DM (2002) Molecular advances in pretargeting radioimunotherapy with bispecific antibodies 1 supported in part by USPHS Grant R01-CA-84379 from the NIH and department of energy grant DE-FG01-00NE22941 (both to R. M. S.).1. Mol Cancer Ther 1(7):553-563
33. Chapman JD, Baer K, Lee J (1983) Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. Cancer Res 43(4):1523-1528 (Pubitemid 13122542)
34. Chen X, Park R, Shahinian AH, Bading JR, Conti PS (2004) Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol 31(1):11-19 (Pubitemid 38115121)
35. Chesler DA, Hales C, Hnatowich DJ, Hoop B (1975) 3-dimensional reconstruction of lung perfusion image with positron detection. J Nucl Med 16(1):80-82
36. Conry BG, Papathanasiou ND, Prakash V, Kayani I, Caplin M, Mahmood S, Bomanji JB (2010) Comparison of Ga-68-DOTATATE and F-18-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 37(1):49-57
37. Cutler CS, Giron MC, Reichert DE, Snyder AZ, Herrero P, Anderson CJ, Quarless DA, Koch SA, Welch MJ (1999) Evaluation of gallium-68 tris(2-mercaptobenzyl)amine: A complex with brain and myocardial uptake. Nucl Med Biol 26(3):305-316 (Pubitemid 29179874)
38. de Jong M, Bakker WH, Krenning EP, Breeman WA, van der Pluijm ME, Bernard BF, Visser TJ, Jermann E, Behe M, Powell P, Macke HR (1997) Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0, d-Phe1, Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 24(4):368-371 (Pubitemid 27183039)
39. De Jong M, Bakker WH, Breeman WA, Bernard BF, Hofland LJ, Visser TJ, Srinivasan A, Schmidt M, Behe M, Macke HR, Krenning EP (1998) Pre-clinical comparison of [DTPA0] octreotide, [DTPA0, Tyr3] octreotide and [DOTA0, Tyr3] octreotide as carriers for somatostatin receptortargeted scintigraphy and radionuclide therapy. Int J Cancer 75(3):406-411 (Pubitemid 28100044)
40. Decristoforo C, Hernandez Gonzalez I, Carlsen J, Rupprich M, Huisman M, Virgolini I, Wester HJ, Haubner R (2008) 68 Ga- and 111In-labelled DOTA-RGD peptides for imaging of alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging 35(8):1507-1515
41. Demmer O, Dijkgraaf I, Schottelius M, Wester HJ, Kessler H (2008) Introduction of functional groups into peptides via N-alkylation. Org Lett 10(10):2015-2018
42. Deshmukh MV, Voll G, Kuhlewein A, Macke H, Schmitt J, Kessler H, Gemmecker G (2005) NMR studies reveal structural differences between the gallium and yttrium complexes of DOTA-D-Phe1-Tyr3-octreotide. J Med Chem 48(5):1506-1514 (Pubitemid 40364558)
43. Dijkgraaf I, Boerman OC (2009) Radionuclide imaging of tumor angiogenesis. Cancer Biother Radiopharm 24(6):637-647
44. Dijkgraaf I, Yim CB, Franssen GM, Schuit RC, Luurtsema G, Liu S, Oyen WJ, Boerman OC (2011) PET imaging of alphavbeta integrin expression in tumours with Ga-labelled mono-, di- and tetrameric RGD peptides. Eur J Nucl Med Mol Imaging 38(1):128-137
45. Dimitrakopoulou-Strauss A, Georgoulias V, Eisenhut M, Herth F, Koukouraki S, Macke HR, Haberkorn U, Strauss LG (2006) Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using Ga-68-DOTATOC PET and comparison with F-18-FDG PET. Eur J Nucl Med Mol Imaging 33(7):823-830 (Pubitemid 43979691)
46. Dimitrakopoulou-Strauss A, Hohenberger P, Haberkorn U, Macke HR, Eisenhut M, Strauss LG (2007) Ga-68-Labeled bombesin studies in patients with gastrointestinal stromal tumors: Comparison with F-18-FDG. J Nucl Med 48(8):1245-1250 (Pubitemid 47242788)
47. Eisenwiener KP, Prata MI, Buschmann I, Zhang HW, Santos AC, Wenger S, Reubi JC, Macke HR (2002) NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67/68 Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors. Bioconjug Chem 13(3):530-541 (Pubitemid 34535940)
48. Erchegyi J, Grace CR, Samant M, Cescato R, Piccand V, Riek R, Reubi JC, Rivier JE (2008) Ring size of somatostatin analogues (ODT-8) modulates receptor selectivity and binding affinity. J Med Chem 51(9):2668-2675
49. Eriksson O, Carlsson F, Blom E, Sundin A, Långström B, Korsgren O, Velikyan I (2011) Preclinical evaluation of a 68Ga-labeled biotin analogue for applications in islet transplantation. Nucl Med Biol 38(6):827
50. Even GA, Green MA (1989) Gallium-68-labeled macroaggregated human serum albumin, 68 Ga-MAA. Int J Radiat Appl Instrum Part B Nucl Med Biol 16(3):319-321 (Pubitemid 19094766)
51. Fani M, Mueller A, Tamma ML, Nicolas G, Rink HR, Cescato R, Reubi JC, Maecke HR (2010) Radiolabeled bicyclic somatostatin-based analogs: A novel class of potential radiotracers for SPECT/PET of neuroendocrine tumors. J Nucl Med 51(11):1771-1779
52. Fani M, Wang X, Nicolas G, Medina C, Raynal I, Port M, Maecke HR (2011) Development of new folate-based PET radiotracers: Preclinical evaluation of Ga-DOTA-folate conjugates. Eur J Nucl Med Mol Imaging 38(1):108-119
53. Fellner M, Baum RP, Kubicek V, Hermann P, Lukes I, Prasad V, Rosch F (2010) PET/CT imaging of osteoblastic bone metastases with Ga-68- bisphosphonates: First human study. Eur J Nucl Med Mol Imaging 37(4):834
54. Forrer F, Uusijarvi H, Waldherr C, Cremonesi M, Bernhardt P, Mueller-Brand J, Maecke HR (2004) A comparison of (111)In-DOTATOC and (111)In-DOTATATE: Biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 31(9):1257-1262 (Pubitemid 39222489)
55. Forssell-Aronsson E, Kjellen E, Mattsson S, Hellstrom M (2002) Medical imaging for improved tumour characterization, delineation and treatment verification. Acta Oncol 41(7-8):604-614 (Pubitemid 36109157)
56. Forster GJ, Santos EB, Smith-Jones PM, Zanzonico P, Larson SM (2006) Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: Strategies for reduction of the renal dose. J Nucl Med 47(1):140-149 (Pubitemid 46768523)
57. Frangioni JV (2009) The problem is background, not signal. Mol Imaging 8(6):303-304
58. Frilling A, Sotiropoulos GC, Radtke A, Malago M, Bockisch A, Kuehl H, Li J, Broelsch CE (2010) The impact of 68 Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg 252(5):850-856
59. Froidevaux S, Eberle AN (2002) Somatostatin analogs and radiopeptides in cancer therapy. Biopolymers 66(3):161-183 (Pubitemid 35285217)
60. Froidevaux S, Eberle AN, Christe M, Sumanovski L, Heppeler A, Schmitt JS, Eisenwiener K, Beglinger C, Macke HR (2002) Neuroendocrine tumor targeting: Study of novel galliumlabeled somatostatin radiopeptides in a rat pancreatic tumor model. Int J Cancer 98(6):930-937 (Pubitemid 34286693)
61. Froidevaux S, Calame-Christe M, Schuhmacher J, Tanner H, Saffrich R, Henze M, Eberle AN (2004) A gallium-labeled DOTA-{alpha}-melanocyte-stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med 45(1):116-123 (Pubitemid 47611617)
62. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, Von Guggenberg E, Bale R, Virgolini IJ (2007) 68 Ga-DOTA-Tyr3- octreotide PET in neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48(4):508-518 (Pubitemid 47571404)
63. Gabriel M, Andergassen U, Putzer D, Kroiss A, Waitz D, Von Guggenberg E, Kendler D, Virgolini IJ (2010) Individualized peptide-related-radionuclide- therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients. Q J Nucl Med Mol Imaging 54(1):92-99
64. Gambhir SS (2002) Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2(9):683-693 (Pubitemid 37328919)
65. Garner RC, LappinG(2006) The phase 0 microdosing concept. Br J Clin Pharmacol 61(4):367-370
66. Gebhardt P, Opfermann T, Saluz HP (2010) Computer controlled Ga-68 milking and concentration system. Appl Radiat Isot 68(6):1057-1059
67. Gehler B, Paulsen F, Oksuz MO, Hauser TK, Eschmann SM, Bares R, Pfannenberg C, Bamberg M, Bartenstein P, Belka C, Ganswindt U (2009) [68 Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning. Radiat Oncol 4:56
68. Ginj M, Chen J, Walter MA, Eltschinger V, Reubi JC, Maecke HR (2005) Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin Cancer Res 11(3):1136-1145 (Pubitemid 40175763)
69. Gold DV, Goldenberg DM, Karacay H, Rossi EA, Chang CH, Cardillo TM, McBride WJ, Sharkey RM (2008) A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma. Cancer Res 68(12):4819-4826
70. Goldenberg DM, Sharkey RM (2007) Novel radiolabeled antibody conjugates. Oncogene 26(25):3734-3744 (Pubitemid 46842708)
71. Goldenberg DM, Sharkey RM, Paganelli G, Barbet J, Chatal JF (2006) Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 24(5):823-834 (Pubitemid 46671186)
72. Goldenberg DM, Rossi EA, Sharkey RM, McBride WJ, Chang CH (2008) Multifunctional antibodies by the dock-and-lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med 49(1):158-163
73. Goldstein MJ, Mitchell EP (2005) Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest 23(4):338-351 (Pubitemid 41656973)
74. Grace CR, Erchegyi J, Samant M, Cescato R, Piccand V, Riek R, Reubi JC, Rivier JE (2008a) Ring size in octreotide amide modulates differently agonist versus antagonist binding affinity and selectivity. J Med Chem 51(9):2676-2681
75. Grace CR, Erchegyi J, Reubi JC, Rivier JE, Riek R (2008b) Three-dimensional consensus structure of sst2-selective somatostatin (SRIF) antagonists by NMR. Biopolymers 89(12):1077-1087
76. Griffiths GL, Chang CH, McBride WJ, Rossi EA, Sheerin A, Tejada GR, Karacay H, Sharkey RM, Horak ID, Hansen HJ, Goldenberg DM (2004) Reagents and methods for PET using bispecific antibody pretargeting and 68 Ga-radiolabeled bivalent hapten-peptide-chelate conjugates. J Nucl Med 45(1):30-39 (Pubitemid 47611605)
77. Haubner R, Kuhnast B, Mang C, Weber WA, Kessler H, Wester HJ, Schwaiger M (2004) Galacto-RGD: Synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem 15(1):61-69
78. Haukkala J, Laitinen I, Luoto P, Iveson P, Wilson I, Karlsen H, Cuthbertson A, Laine J, Leppanen P, Yla-Herttula S, Knuuti J, Roivainen A (2009) (68)Ga-DOTA-RGD peptide: Biodistribution and binding into atherosclerotic plaques in mice. Eur J Nucl Med Mol Imaging
79. Hayes RL, Carlton JE, Kuniyasu Y (1981) A new method for labeling microspheres with 68 Ga. Eur J Nucl Med 6(11):531-533
80. Henze M, Schuhmacher J, Hipp P, Kowalski J, Becker DW, Doll J, Macke HR, Hofmann M, Debus J, Haberkorn U (2001) PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: First results in patients with meningiomas. J Nucl Med 42(7):1053-1056 (Pubitemid 32595304)
81. Henze M, Schuhmacher J, Dimitrakopoulou-Strauss A, Strauss LG, Macke HR, Eisenhut M, Haberkorn U (2004) Exceptional increase in somatostatin receptor expression in pancreatic neuroendocrine tumour, visualised with Ga-68-DOTATOC PET. Eur J Nucl Med Mol Imaging 31(3):466 (Pubitemid 38314091)
82. Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J, Macke HR, Eisenhut M, Debus J, Haberkorn U (2005) Characterization of 68 Ga-DOTA-DPhe1-Tyr3-octreotide kinetics in patients with meningiomas. J Nucl Med 46(5):763-769
83. Heppeler A, Froidevaux S, Macke HR, Jermann E, Behe M, Powell P, Hennig M (1999) Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy. Chem Eur J 5(7):1974-1981
84. Heppeler A, Froidevaux S, Eberle AN, Maecke HR (2000) Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 7:971-994
85. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Di Maria MV, Veve R, Bremmes RM, Baron AE, Zeng C, Franklin WA (2003) Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21(20):3798-3807 (Pubitemid 46606235)
86. Hoffend J, Mier W, Schuhmacher J, Schmidt K, Dimitrakopoulou-Strauss A, Strauss LG, Eisenhut M, Kinscherf R, Haberkorn U (2005) Gallium-68-DOTA-albumin as a PET bloodpool marker: Experimental evaluation in vivo. Nucl Med Biol 32(3):287-292 (Pubitemid 40488386)
87. Hofland LJ, Breeman WA, Krenning EP, de Jong M, Waaijers M, van Koetsveld PM, Macke HR, Lamberts SW (1999) Internalization of [DOTA degrees,125I-Tyr3] octreotide by somatostatin receptor-positive cells in vitro and in vivo: Implications for somatostatin receptor-targeted radio-guided surgery. Proc Assoc Am Physicians 111(1):63-69 (Pubitemid 29047111)
88. Hofmann M, Maecke H, Borner R, Weckesser E, Schoffski P, Oei L, Schumacher J, Henze M, Heppeler A, Meyer J, Knapp H (2001) Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: Preliminary data. Eur J Nucl Med 28(12):1751-1757
89. Hofmann M, Machtens S, Stief C, Langer F, Boerner AR, Maecke H, Knapp WH (2004a) Feasibility of Ga-68-DOTABOM PET in prostate carcinoma patients. Eur J Nucl Med Mol Imaging 31:S253-S253
90. Hofmann M, Beyer T, Boerner A, Mueller J, Frilling A, Maecke H, Muller S, Clauss R, Bockisch A, Knapp W (2004b) Improved imaging of SMS PET (Ga-68-DOTATOC) by PET/CT in carcinoids. Eur J Nucl Med Mol Imaging 31:S339
91. Hoigebazar L, Jeong JM, Choi SY, Choi JY, Shetty D, Lee YS, Lee DS, Chung JK, Lee MC, Chung YK (2010) Synthesis and characterization of nitroimidazole derivatives for 68 Galabeling and testing in tumor xenografted mice. J Med Chem 53(17):6378-6385
92. Hong H, Sun J, Cai W (2008) Radionuclide-based cancer imaging targeting the carcinoembryonic antigen. Biomark Insights 3:435-451
93. Hsiao YM, Mathias CJ, Wey SP, Fanwick PE, Green MA (2009) Synthesis and biodistribution of lipophilic and monocationic gallium radiopharmaceuticals derived from N,N'-bis(3-aminopropyl)-N,N'-dimethylethylenediamine: Potential agents for PET myocardial imaging with Ga-68. Nucl Med Biol 36(1):39-45
94. Indrevoll B, Kindberg GM, Solbakken M, Bjurgert E, Johansen JH, Karlsen H, Mendizabal M, Cuthbertson A (2006) NC-100717: A versatile RGD peptide scaffold for angiogenesis imaging. Bioorg Med Chem Lett 16(24):6190-6193 (Pubitemid 44709917)
95. Janson ET, Sorbye H, Welin S, Federspiel B, Gronbaek H, Hellman P, Mathisen O, Mortensen J, Sundin A, Thiis-Evensen E, Valimaki MJ, Oberg K, Knigge U (2010) Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Acta Oncol 49(6):740-756
96. Janssen M, Oyen WJ, Massuger LF, Frielink C, Dijkgraaf I, Edwards DS, Radjopadhye M, Corstens FH, Boerman OC (2002) Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm 17(6):641-646 (Pubitemid 36025945)
97. Jeong JM, Hong MK, Chang YS, Lee YS, Kim YJ, Cheon GJ, Lee DS, Chung JK, Lee MC (2008) Preparation of a promising angiogenesis PET imaging agent: Ga-68-labeled c(RGDyK)-isothiocyanatobenzyl-1,4,7-triazacyclononane-1,4,7- triacetic acid and feasibility studies in mice. J Nucl Med 49(5):830-836
98. Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, Dickson J, Caplin M, Ell PJ (2008) Functional imaging of neuroendocrine tumors with combined PET/CT using 68 Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and 18F-FDG. Cancer 112(11):2447-2455
99. Kotzerke J, Andreeff M, Wunderlich G (2010) PET aerosol lung scintigraphy using galligas. Eur J Nucl Med Mol Imaging 37(1):175-177
100. Koukouraki S, Strauss LG, Georgoulias V, Schuhmacher J, Haberkorn U, Karkavitsas N, Dimitrakopoulou-Strauss A (2006a) Evaluation of the pharmacokinetics of 68 Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 33(4):460-466
101. Koukouraki S, Strauss LG, Georgoulias V, Eisenhut M, Haberkorn U, Dimitrakopoulou-Strauss A (2006b) Comparison of the pharmacokinetics of Ga-68-DOTATOC and F-18 FDG in patients with metastatic neuroendocrine tumours scheduled for Y-90-DOTATOC therapy. Eur J Nucl Med Mol Imaging 33(10):1115-1122 (Pubitemid 44484467)
102. Kowalski J, Henze M, Schuhmacher J, Macke HR, Hofmann M, Haberkorn U (2003) Evaluation of positron emission tomography imaging using [68 Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 5(1):42-48 (Pubitemid 36596544)
103. Långström B, Velikyan I, Bergström M, Lindhe Ö (2008) 68Ga-labeled peptide-based radiopharmaceuticals. WO/2008/026040
104. Lankinen P, Maekinen TJ, Poeyhoenen TA, Virsu P, Salomaeki S, Hakanen AJ, Jalkanen S, Aro HT, Roivainen A (2008) Ga-68-DOTAVAP-P1 PET imaging capable of demonstrating the phase of inflammation in healing bones and the progress of infection in osteomyelitic bones. Eur J Nucl Med Mol Imaging 35(2):352-364
105. Laven M, Velikyan I, Djodjic M, Ljung J, Berglund O, Markides K, Langstrom B, Wallenborg S (2005) Imaging of peptide adsorption to microfluidic channels in a plastic compact disc using a positron emitting radionuclide. Lab Chip 5(7):756-763 (Pubitemid 40980104)
106. Lavén M, Wallenborg S, Velikyan I, Bergstrom S, Djodjic M, Ljung J, Berglund O, Edenwall N, Markides KE, Langstrom B (2004) Radionuclide imaging of miniaturized chemical analysis systems. Anal Chem 76(23):7102-7108 (Pubitemid 39600886)
107. Lendvai G, Velikyan I, Bergstrom M, Estrada S, Laryea D, Valila M, Salomaki S, Langstrom B, Roivainen A (2005) Biodistribution of 68Ga-labelled phosphodiester, phosphorothioate, and 2'-O-methyl phosphodiester oligonucleotides in normal rats. Eur J Pharm Sci 26(1):26-38 (Pubitemid 41097258)
108. Lendvai G, Velikyan I, Estrada S, Eriksson B, Langstrom B, Bergstrom M (2008) Biodistribution of (68)Ga-labeled LNA-DNA mixmer antisense oligonucleotides for rat chromogranin-A. Oligonucleotides 18(1):33-49
109. Lendvai G, Monazzam A, Velikyan I, Eriksson B, Josephsson R, Langstrom B, Bergstrom M, Estrada S (2009a) Non-hybridization saturable mechanisms play a role in the uptake of (68)Ga-labeled LNA-DNA mixmer antisense oligonucleotides in rats. Oligonucleotides 19(3):223-232
110. Lendvai G, Estrada S, Bergstrom M (2009b) Radiolabelled oligonucleotides for imaging of gene expression with PET. Curr Med Chem 16(33):4445-4461
111. Li ZB, Chen K, Chen X (2008) (68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression. Eur J Nucl Med Mol Imaging 35(6):1100-1108
112. Lincke T, Singer J, Kluge R, Sabri O, Paschke R (2009) Relative quantification of indium-111 pentetreotide and gallium-68 DOTATOC uptake in the thyroid gland and association with thyroid pathologies. Thyroid 19(4):381-389
113. Liu S (2006) Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging. Mol Pharm 3(5):472-487 (Pubitemid 44639125)
114. Liu S, Edwards DS (1999) Tc-99 m-labeled small peptides as diagnostic radiopharmaceuticals. Chem Rev 99(9):2235-2268
115. Liu Z, Niu G, Shi J, Liu S, Wang F, Chen X (2009) (68)Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: Promising agents for tumor integrin alphavbeta3 PET imaging. Eur J Nucl Med Mol Imaging 36(6):947-957
116. Luboldt W, Zophel K, Wunderlich G, Abramyuk A, Luboldt HJ, Kotzerke J (2010) Visualization of somatostatin receptors in prostate cancer and its bone metastases with Ga-68-DOTATOC PET/CT. Mol Imaging Biol 12(1):78-84
117. Lundqvist H, Tolmachev V (2002) Targeting peptides and positron emission tomography. Biopolymers 66(6):381-392 (Pubitemid 36433533)
118. Maecke HR (2005) Radiolabeled peptides in nuclear oncology: Influence of peptide structure and labeling strategy on pharmacology. Ernst Schering Res Found Workshop 49:43-72
119. Maecke HR, Hofmann M, Haberkorn U (2005) (68)Ga-Labeled peptides in tumor imaging. J Nucl Med 46(Suppl 1):172S-178S
120. Makinen TJ, Lankinen P, Poyhonen T, Jalava J, Aro HT, Roivainen A (2005) Comparison of F-18-FDG and Ga-68 PET imaging in the assessment of experimental osteomyelitis due to Staphylococcus aureus. Eur J Nucl Med Mol Imaging 32(11):1259-1268 (Pubitemid 41598716)
121. Mansi R, Wang X, Forrer F, Waser B, Cescato R, Graham K, Borkowski S, Reubi JC, Maecke HR (2011) Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging 38(1):97-107
122. Maschauer S, Einsiedel J, Hocke C, Hubner H, Kuwert T, Gmeiner P, Prante O (2010) Synthesis of a Ga-68-labeled peptoid-peptide hybrid for imaging of neurotensin receptor expression in vivo. ACS Med Chem Lett 1(5):224-228
123. Mathias CJ, Green MA (2008) A convenient route to Ga-68 Ga-MAA for use as a particulate PET perfusion tracer. Appl Radiat Isot 66(12):1910-1912
124. Mathias CJ, Lewis MR, Reichert DE, Laforest R, Sharp TL, Lewis JS, Yang ZF, Waters DJ, Snyder PW, Low PS, Welch MJ, Green MA (2003) Preparation of 66 Ga- and 68 Ga-labeled Ga(III)-deferoxamine-folate as potential folate-receptor-targeted PET radiopharmaceuticals. Nucl Med Biol 30(7):725-731 (Pubitemid 37123129)
125. Maus S, Buchholz H-G, Ament S, Brochhausen C, Bausbacher N, Schreckenberger M (2011) Labelling of commercially available human serum albumin kits with 68 Ga as surrogates for 99mTc-MAA microspheres. Appl Radiat Isot 69(1):171-175
126. Maziere B, Loc'h C, Steinling M, Comar D (1986) Stable labelling of serum albumin microspheres with gallium-68. Int J Rad Appl Instrum A 37(4):360-361
127. Meier G, Waldherr C, Herrmann R, Maecke H, Mueller-Brand J, Pless M (2004) Successful targeted radiotherapy with 90Y-DOTATOC in a patient with Merkel cell carcinoma. A case report. Oncology 66(2):160-163 (Pubitemid 38608384)
128. Meyer GJ, Macke H, Schuhmacher J, Knapp WH, Hofmann M (2004) 68 Ga-Labelled DOTAderivatised peptide ligands. Eur J Nucl Med Mol Imaging 31(8):1097-1104
129. Mier W, Hoffend J, Kramer S, Schuhmacher J, Hull WE, Eisenhut M, Haberkorn U (2005) Conjugation of DOTA using isolated phenolic active esters: The labeling and biodistribution of albumin as blood pool marker. Bioconjug Chem 16(1):237-240
130. Milker-Zabel S, Zabel-du Bois A, Henze M, Huber P, Schulz-Ertner D, Hoess A, Haberkorn U, Debus J (2006) Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68 Ga]-DOTATOCPET. Int J Radiat Oncol Biol Phys 65(1):222-227
131. Mintun MA, Terpogossian MM, Green MA, Lich LL, Schuster DP (1986) Quantitative measurement of regional pulmonary blood-flow with positron emission tomography. J Appl Physiol 60(1):317-326 (Pubitemid 16024052)
132. Mintun MA, Dennis DR, Welch MJ, Mathias CJ, Schuster DP (1987) Measurements of pulmonary vascular permeability with pet and gallium-68 transferrin. J Nucl Med 28(11):1704-1716 (Pubitemid 17160289)
133. Mitterhauser M, Toegel S, Wadsak W, Lanzenberger RR, Mien LK, Kuntner C, Wanek T, Eidherr H, Ettlinger DE, Viernstein H, Kluger R, Dudczak R, Kletter K (2007) Pre vivo, ex vivo and in vivo evaluations of Ga-68-EDTMP. Nucl Med Biol 34(4):391-397
134. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9(1):61-72
135. Mukai T, Suwada J, Sano K, Okada M, Yamamoto F, MaedaM(2009) Design of Ga-DOTA-based bifunctional radiopharmaceuticals: Two functional moieties can be conjugated to radiogallium-DOTA without reducing the complex stability. Bioorg Med Chem 17(13):4285-4289
136. Mutic S, Malyapa RS, Grigsby PW, Dehdashti F, Miller TR, Zoberi I, Bosch WR, Esthappan J, Low DA (2003) PET-guided IMRT for cervical carcinoma with positive para-aortic lymph nodes-a dose-escalation treatment planning study. Int J Radiat Oncol Biol Phys 55(1):28-35 (Pubitemid 36020341)
137. Nanni C, Errani C, Boriani L, Fantini L, Ambrosini V, Boschi S, Rubello D, Pettinato C, Mercuri M, Gasbarrini A, Fanti S (2010) 68 Ga-citrate PET/CT for evaluating patients with infections of the bone: Preliminary results. J Nucl Med 51(12):1932-1936
138. Neal DE, Mellon K (1992) Epidermal growth factor receptor and bladder cancer: A review. Urol Int 48(4):365-371
139. Otte A, Jermann E, Behe M, Goetze M, Bucher HC, Roser HW, Heppeler A, Mueller-Brand J, Maecke HR (1997) DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 24(7):792-795 (Pubitemid 27356860)
140. Petrik M, Haas H, Dobrozemsky G, Lass-Florl C, Helbok A, Blatzer M, Dietrich H, Decristoforo C (2010) 68 Ga-siderophores for PET imaging of invasive pulmonary aspergillosis: Proof of principle. J Nucl Med 51(4):639-645
141. Pettinato C, Sarnelli A, Di Donna M, Civollani S, Nanni C, Montini G, Di Pierro D, Ferrari M, Marengo M, Bergamini C (2008) (68)Ga-DOTANOC: Biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging 35(1):72-79 (Pubitemid 350234154)
142. Pless M, Waldherr C, Maecke H, Buitrago C, Herrmann R, Mueller-Brand J (2004) Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: A pilot trial. Lung Cancer 45(3):365-371 (Pubitemid 39037718)
143. Plossl K, Chandra R, Qua WC, Lieberman BP, Kung MP, Zhou R, Huang B, Kung HF (2008) A novel gallium bisaminothiolate complex as a myocardial perfusion imaging agent. Nucl Med Biol 35(1):83-90 (Pubitemid 350298244)
144. Prasad V, Baum RP (2010) Biodistribution of the Ga-68 labeled somatostatin analogue DOTANOC in patients with neuroendocrine tumors: Characterization of uptake in normal organs and tumor lesions. Q J Nucl Med Mol Imaging 54(1):61-67
145. Prinsen K, Li JJ, Vanbilloen H, Vermaelen P, Devos E, Mortelmans L, Bormans G, Ni YC, Verbruggen A (2010) Development and evaluation of a Ga-68 labeled pamoic acid derivative for in vivo visualization of necrosis using positron emission tomography. Bioorg Med Chem 18(14):5274-5281
146. Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G, Decristoforo C, Bale RJ, Jaschke W, Virgolini IJ (2009) Bone metastases in patients with neuroendocrine tumor: 68 Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 50(8):1214-1221
147. Putzer D, Gabriel M, Kendler D, Henninger B, Knoflach M, Kroiss A, Vonguggenberg E, Warwitz B, Virgolini IJ (2010) Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients. Q J Nucl Med Mol Imaging 54(1):68-75
148. Ren G, Zhang R, Liu Z, Webster JM, Miao Z, Gambhir SS, Syud FA, Cheng Z (2009) A 2-helix small protein labeled with 68 Ga for PET imaging of HER2 expression. J Nucl Med 50(9):1492-1499
149. Reubi JC (2001) Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 28(7):836-846 (Pubitemid 32662546)
150. Reubi JC, Maecke HR (2008) Peptide-based probes for cancer imaging. J Nucl Med 49(11): 1735-1738
151. Reubi JC, Schär J-C, Waser B, Wenger S, Heppeler A, Schmitt JS, Mäcke HR (2000) Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med Mol Imaging 27(3):273-282 (Pubitemid 30167697)
152. Reubi JC, Macke HR, Krenning EP (2005) Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 46(Suppl 1):67S-75S
153. Richter T, Bergmann R, Pietzsch J, Kozle I, Hofheinz F, Schiller E, Ragaller M, van den Hoff J (2010) Effects of posture on regional pulmonary blood flow in rats as measured by PET. J Appl Physiol 108(2):422-429
154. Riss PJ, Kroll C, Nagel V, Rosch F (2008) NODAPA-OH and NODAPA-(NCS)n: Synthesis, 68 Ga-radiolabelling and in vitro characterisation of novel versatile bifunctional chelators for molecular imaging. Bioorg Med Chem Lett 18(20):5364-5367
155. Rivier JE, Kirby DA, Erchegyi J, Waser B, Eltschinger V, Cescato R, Reubi JC (2005) Somatostatin receptor 1 selective analogues: 3 Dicyclic peptides. J Med Chem 48(2):515-522 (Pubitemid 40139794)
156. Rizzello A, Di Pierro D, Lodi F, Trespidi S, Cicoria G, Pancaldi D, Nanni C, Marengo M, Marzola MC, Ai-Nahhas A, Rubello D, Boschi S (2009) Synthesis and quality control of Ga-68 citrate for routine clinical PET. Nucl Med Commun 30(7):542-545
157. Roivainen A, Tolvanen T, Salomaki S, Lendvai G, Velikyan I, Numminen P, Valila M, Sipila H, Bergstrom M, Harkonen P, Lonnberg H, Langstrom B (2004) 68 Ga-labeled oligonucleotides for in vivo imaging with PET. J Nucl Med 45(2):347-355 (Pubitemid 47618660)
158. Rominger A, Saam T, Vogl E, Ubleis C, la Fougere C, Forster S, Haug A, Cumming P, Reiser MF, Nikolaou K, Bartenstein P, Hacker M (2010) In vivo imaging of macrophage activity in the coronary arteries using 68 Ga-DOTATATE PET/CT: Correlation with coronary calcium burden and risk factors. J Nucl Med 51(2):193-197
159. Rossi EA, Rossi DL, Stein R, Goldenberg DM, Chang CH (2010) A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells. Cancer Res 70(19):7600-7609
160. Sainz-Esteban A, Prasad V, Baum RP (2010) Pancreatic neuroendocrine tumor with involvement of the inferior mesenteric vein diagnosed by Ga-68 DOTA-TATE PET/CT. Clin Nucl Med 35(1):40-41
161. Sandstrom K, Haylock AK, Velikyan I, Spiegelberg D, Kareem H, Tolmachev V, Lundqvist H, Nestor M (2011) Improved Tumor-to-Organ Ratios of a novel (67)Ga-human epidermal growth factor radionuclide conjugate with preadministered antiepidermal growth factor receptor affibody molecules. Cancer Biother Radiopharm 26(5):593-600
162. Schiller E, Bergmann R, Pietzsch J, Noll B, Sterger A, Johannsen B, Wunderlich G, Pietzsch HJ (2008) Yttrium-86-labelled human serum albumin microspheres: Relation of surface structure with in vivo stability. Nucl Med Biol 35(2):227-232
163. Schmidt K, Hoffend J, Altmann A, Strauss LG, Dimitrakopoulou-Strauss A, Engelhardt B, Koczan D, Peter J, Dengler TJ, Mier W, Eisenhut M, Haberkorn U, Kinscherf R (2006) Angiostatin overexpression in Morris hepatoma results in decreased tumor growth but increased perfusion and vascularization. J Nucl Med 47(3):543-551
164. Schmitt A, Bernhardt P, Nilsson O, Ahlman H, Kolby L, Maecke HR, Forssell-Aronsson E (2004) Radiation therapy of small cell lung cancer with 177Lu-DOTA-Tyr3-octreotate in an animal model. J Nucl Med 45(9):1542-1548 (Pubitemid 47618508)
165. Schmitt A, Bernhardt P, Nilsson O, Ahlman H, Kolby L, Forssell-Aronsson E (2005) Differences in biodistribution between 99 mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTATyr3-octreotate in a small cell lung cancer animal model. Cancer Biother Radiopharm 20(2): 231-236 (Pubitemid 40696108)
166. Schoffelen R, Sharkey RM, Goldenberg DM, Franssen G, McBride WJ, Rossi EA, Chang CH, Laverman P, Disselhorst JA, Eek A, van der Graaf WT, Oyen WJ, Boerman OC (2010) Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigenexpressing tumors with a bispecific antibody and a 68 Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts. Mol Cancer Ther 9(4):1019-1027
167. Schottelius M, Berger S, Poethko T, Schwaiger M, Wester HJ (2008) Development of novel Ga-68- and F-18-labeled GnRH-I analogues with high GnRHR-targeting efficiency. Bioconj Chem 19(6):1256-1268 (Pubitemid 351874949)
168. Schuhmacher J, Kaul S, Klivenyi G, Junkermann H, Magener A, Henze M, Doll J, Haberkorn U, Amelung F, Bastert G (2001a) Immunoscintigraphy with positron emission tomography: gallium-68 chelate imaging of breast cancer pretargeted with bispecific anti-MUC1/anti-Ga chelate antibodies. Cancer Res 61(9):3712-3717 (Pubitemid 32694984)
169. Schuhmacher J, Klivenyi G, Kaul S, Henze M, Matys R, Hauser H, Clorius J (2001b) Pretargeting of human mammary carcinoma xenografts with bispecific anti-MUC1/anti-Ga chelate antibodies and immunoscintigraphy with PET. Nucl Med Biol 28(7):821-828 (Pubitemid 32900640)
170. Schuhmacher J, Zhang H, Doll J, Macke HR, Matys R, Hauser H, Henze M, Haberkorn U, Eisenhut M (2005) GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68 Ga-labeled bombesin(6-14) analog. J Nucl Med 46(4):691-699 (Pubitemid 41721868)
171. Schuster DP (1998) The evaluation of lung function with PET. Semin Nucl Med 28(4):341-351 (Pubitemid 28478047)
172. Schuster DP, Kaplan JD, Gauvain K, Welch MJ, Markham J (1995) Measurement of regional pulmonary blood-flow with PET. J Nucl Med 36(3):371-377
173. Schuster DP, Stark T, Stephenson J, Royal H (2002) Detecting lung injury in patients with pulmonary edema. Intensive Care Med 28(9):1246-1253 (Pubitemid 35025041)
174. Sharkey RM, Cardillo TM, Rossi EA, Chang CH, Karacay H, McBride WJ, Hansen HJ, Horak ID, Goldenberg DM (2005) Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med 11(11):1250-1255 (Pubitemid 43093674)
175. Sharkey RM, Karacay H, Litwin S, Rossi EA, McBride WJ, Chang CH, Goldenberg DM (2008) Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. Cancer Res 68(13):5282-5290
176. Sharkey RM, Rossi EA, McBride WJ, Chang CH, Goldenberg DM (2010a) Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy. Semin Nucl Med 40(3):190-203
177. Sharkey RM, Rossi EA, Chang CH, Goldenberg DM (2010b) Improved cancer therapy and molecular imaging with multivalent, multispecific antibodies. Cancer Biother Radiopharm 25(1):1-12
178. Sharma V, Prior JL, Belinsky MG, Kruh GD, Piwnica-Worms D (2005) Characterization of a 67 Ga/68 Ga radiopharmaceutical for SPECT and PET of MDR1 P-glycoprotein transport activity in vivo: validation in multidrug-resistant tumors and at the blood-brain barrier. J Nucl Med 46(2):354-364 (Pubitemid 43073447)
179. Shetty D, Jeong JM, Ju CH, Lee YS, Jeong SY, Choi JY, Yang BY, Lee DS, Chung JK, Lee MC (2010a) Synthesis of novel 68 Ga-labeled amino acid derivatives for positron emission tomography of cancer cells. Nucl Med Biol 37(8):893-902
180. Shetty D, Jeong JM, Ju CH, Kim YJ, Lee JY, Lee YS, Lee DS, Chung JK, Lee MC (2010b) Synthesis and evaluation of macrocyclic amino acid derivatives for tumor imaging by gallium-68 positron emission tomography. Bioorg Med Chem 18(21):7338-7347
181. Silvola J, Autio A, Luoto P, Jalkanen S, Roivainen A (2010) Preliminary evaluation of novel 68 Ga-DOTAVAP-PEG-P2 peptide targeting vascular adhesion protein-1. Clin Physiol Funct Imaging 30(1):75-78
182. Smith-Jones PM, Stolz B, Burns C, Albert R, Reist HW, Fridrich R, Mäcke HM (1994) Gallium-67/gallium-68-[DFO]-octreotide- a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: Synthesis and radiolabeling in vitro and preliminary in vivo studies. J Nucl Med 35(2):317-325 (Pubitemid 24048322)
183. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM (2004) Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 22(6):701-706 (Pubitemid 38702826)
184. Smith-Jones PM, Solit D, Afroze F, Rosen N, Larson SM (2006) Early tumor response to Hsp90 therapy using HER2 PET: Comparison with 18F-FDG PET. J Nucl Med 47(5):793-796 (Pubitemid 46768442)
185. Somasundaram C, Matzku S, Schuhmacher J, Zöller M (1993) Development of a bispecific monoclonal antibody against a gallium-67 chelate and the human melanoma-associated antigen p97 for potential use in pretargeted immunoscintigraphy. Cancer Immunol Immunother 36(5):337-345 (Pubitemid 23106004)
186. Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J (2010) The Role of 68 Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med 51(6):875-882
187. Steinling M, Baron JC, Maziere B, Lasjaunias P, Loc'h C, Cabanis EA, Guillon B (1985) Tomographic measurement of cerebral blood flow by the 68Ga-labelled-microsphere and continuous-C15O2-inhalation methods. Eur J Nucl Med Mol Imaging 11(1):29-32
188. Tan EH, Goh SW (2010) Exploring new frontiers in molecular imaging: Emergence of Ga PET/CT. World J Radiol 2(2):55-67
189. Tavitian B (2005) Oligonucleotides as radiopharmaceuticals. Ernst Schering Res Found Workshop 49:1-34
190. Thakur ML (1995) Radiolabelled peptides: Now and the future. Nucl Med Commun 16(9):724-732
191. Theeraladanon C, Takahashi N, Shiina M, Hamada K, Takada Y, Endo H, Tateishi U, Oka T, Ogata K, Inoue T (2010) Rational approach to the synthesis, evaluation, and 68 Ga labeling of a novel 4-anilinoquinoline epidermal growth factor receptor inhibitor as a new imaging agent that selectively targets the epidermal growth factor receptor tyrosine kinase. Cancer Biother Radiopharm 25(4):479-485
192. Thews O, Dillenburg W, Fellner M, Buchholz HG, Bausbacher N, Schreckenberger M, Rosch F (2010) Activation of P-glycoprotein (Pgp)-mediated drug efflux by extracellular acidosis: In vivo imaging with Ga-68-labelled PET tracer. Eur J Nucl Med Mol Imaging 37(10):1935-1942
193. Toegel S, Wadsak W, Mien LK, Viernstein H, Kluger R, Eidherr H, Haeusler D, Kletter K, Dudczak R, Mitterhauser M (2008) Preparation and pre-vivo evaluation of no-carrier-added, carrier-added and cross-complexed Ga-68-EDTMP formulations. Eur J Pharm Biopharm 68(2):406-412
194. Tofilon PJ, Saxman S, Coleman CN (2003) Molecular targets for radiation therapy: Bringing preclinical data into clinical trials. Clin Cancer Res 9(10 Pt 1):3518-3520 (Pubitemid 37169213)
195. Tolmachev V (1800) Stone-Elander S (2010) Radiolabelled proteins for positron emission tomography: Pros and cons of labelling methods. Biochim Biophys Acta 5:487-510
196. Tolmachev V, Orlova A (2009) Update on affibody molecules for in vivo imaging of targets for cancer therapy. Minerva Biotecnologica 21(1):21-30
197. Tolmachev V, Friedman M, Sandstrom M, Eriksson TLJ, Rosik D, Hodik M, Stahl S, Frejd FY, Orlova A (2009) Affibody molecules for epidermal growth factor receptor targeting in vivo: Aspects of dimerization and labeling chemistry. J Nucl Med 50(2):274-283
198. Tolmachev V, Velikyan I, Sandstrom M, Orlova A (2010) A HER2-binding Affibody molecule labelled with 68 Ga for PET imaging: Direct in vivo comparison with the 111In-labelled analogue. Eur J Nucl Med Mol Imaging 37(7):1356-1367
199. Traub-Weidinger T, Von Guggenberg E, Dobrozemsky G, Kendler D, Eisterer W, Bale R, Putzer D, Gabriel M, Virgolini I (2010) Preliminary experience with Ga-68-DOTA-lanreotide positron emission tomography. Q J Nucl Med Mol Imaging 54(1):52-60
200. Tsang BW, Mathias CJ, Green MA (1993) A gallium-68 radiopharmaceutical that is retained in myocardium: 68Ga[(4,6-MeO2sal)2BAPEN]+. J Nucl Med 34(7):1127-1131 (Pubitemid 23191329)
201. Ujula T, Salomaki S, Virsu P, Lankinen P, Makinen TJ, Autio A, Yegutkin GG, Knuuti J, Jalkanen S, Roivainen A (2009) Synthesis, Ga-68 labeling and preliminary evaluation of DOTA peptide binding vascular adhesion protein-1: A potential PET imaging agent for diagnosing osteomyelitis. Nucl Med Biol 36(6):631-641
202. Van Riet J, Rattat D, Verbruggen A, Mortelmans L, Mottaghy FM (2009) Ga-68 DOTATOC PET/CT changed the therapeutic course of a patient with the sudden onset of vision problems. Clin Nucl Med 34(1):27-28
203. Velikyan I (2005) Synthesis, characterization and application of 68Ga-Labelled Macromolecules http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva- 5876. In: Doctoral Thesis from the Faculty of Sciences and Technology, Uppsala University, Swedened
204. Velikyan I (2011) Positron emitting [68Ga]Ga-based imaging agents: Chemistry and diversity. Med Chem 7:338-372
205. Velikyan I, Långström B (2004) Microwave method for preparing radiolabelled gallium complexes. WO/2004/089425
206. Velikyan I, Långström B (2006) 68Ga-Labeling of a free and macromolecule conjugated macrocyclic chelator at room temperature. WO/2008/026051
207. Velikyan I, Beyer GJ, Langstrom B (2004a) Microwave-supported preparation of 68Gabioconjugates with high specific radioactivity. Bioconj Chem 15(3):554-560 (Pubitemid 38657861)
208. Velikyan I, Lendvai G, Valila M, Roivainen A, Yngve U, Bergstrom M, Langstrom B (2004b) Microwave accelerated 68Ga-labelling of oligonucleotides. J Labelled Comp Radiopharm 47(1):79-89
209. Velikyan I, Långström B, Beyer G (2004) Method of obtaining gallium-68 and use thereof and device for carrying out said method. WO/2004/089517 A1, October 21
210. Velikyan I, Sundberg AL, Lindhe O, Hoglund AU, Eriksson O, Werner E, Carlsson J, Bergstrom M, Langstrom B, Tolmachev V (2005) Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. J Nucl Med 46(11):1881-1888 (Pubitemid 46196651)
211. Velikyan I, Liljegren Sundberg Å, Långström B, Tolmachev V (2006) [68Ga] DOTA hEGF for non-invasive measurement of EGFR expression in tumors using PET. WO/2006/090232
212. Velikyan I, Beyer GJ, Bergstrom-Pettermann E, Johansen P, Bergstrom M, Langstrom B (2008a) The importance of high specific radioactivity in the performance of (68)Ga-labeled peptide. Nucl Med Biol 35(5):529-536
213. Velikyan I, Maecke H, Langstrom B (2008b) Convenient preparation of 68 Ga-based PETradiopharmaceuticals at room temperature. Bioconjug Chem 19(2):569-573 (Pubitemid 351294931)
214. Velikyan I, Sundin A, Eriksson B, Lundqvist H, Sorensen J, Bergstrom M, Langstrom B (2010) In vivo binding of [68 Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours-impact of peptide mass. Nucl Med Biol 37(3):265-275
215. Versari A, Camellini L, Carlinfante G, Frasoldati A, Nicoli F, Grassi E, Gallo C, Giunta FP, Fraternali A, Salvo D, Asti M, Azzolini F, Iori V, Sassatelli R (2010) Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: A single-centre retrospective study. Clin Nucl Med 35(5):321-328
216. Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, Papathanasiou ND, Pepe G, Oyen W, De Cristoforo C, Chiti A (2010) Procedure guidelines for PET/CT tumour imaging with 68 Ga-DOTA-conjugated peptides: 68 Ga-DOTA-TOC, 68 Ga-DOTA-NOC, 68 Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging 37(10):2004-2010
217. Vosjan MJ, Perk LR, Roovers RC, Visser GW, Stigter-van Walsum M, van Bergen En Henegouwen PM, van Dongen GA (2011) Facile labelling of an anti-epidermal growth factor receptor nanobody with (68)Ga via a novel bifunctional desferal chelate for immuno-PET. Eur J Nucl Med Mol Imaging
218. Wagner SJ, Welch MJ (1979) Gallium-68 labeling of albumin and albumin microspheres. J Nucl Med 20(5):428-433
219. Walker RA, Dearing SJ (1999) Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. Breast Cancer Res Treat 53(2):167-176 (Pubitemid 29161123)
220. Watine J, Miedouge M, Friedberg B (2001) Carcinoembryonic antigen as an independent prognostic factor of recurrence and survival in patients resected for colorectal liver metastases: A systematic review. Dis Colon Rectum 44(12):1791-1799 (Pubitemid 34031435)
221. Wei L, Miao Y, Gallazzi F, Quinn TP, Welch MJ, Vavere AL, Lewis JS (2007) Gallium-68-labeled DOTA-rhenium-cyclized alpha-melanocyte-stimulating hormone analog for imaging of malignant melanoma. Nucl Med Biol 34(8):945-953 (Pubitemid 350061168)
222. Welch MJ, Thakur ML, Coleman RE, Patel M, Siegel BA, Ter-Pogossian MM (1977) Gallium-68 labeled red cells and platelets new agents for positron tomography. J Nucl Med 18(6):558-562 (Pubitemid 8128897)
223. Wild D, Schmitt JS, Ginj M, Macke HR, Bernard BF, Krenning E, De Jong M, Wenger S, Reubi JC (2003) DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 30(10):1338-1347 (Pubitemid 37247950)
224. Wild D, Macke HR, Waser B, Reubi JC, Ginj M, Rasch H, Muller-Brand J, Hofmann M (2005) 68 Ga-DOTANOC: A first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging 32(6):724 (Pubitemid 40897499)
225. Wild D, Wicki A, Mansi R, Behe M, Keil B, Bernhardt P, Christofori G, Ell PJ, Macke HR (2010) Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT. J Nucl Med 51(7):1059-1067
226. Win Z, Al-Nahhas A, Towey D, Todd JF, Rubello D, Lewington V, Gishen P (2007) 68 Ga-DOTATATE PET in neuroectodermal tumours: First experience. Nucl Med Commun 28(5):359-363 (Pubitemid 46569168)
227. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM (2003) Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 200(3):290-297 (Pubitemid 36827302)
228. Wunderlich G, Schiller E, Bergmann R, Pietzsch H-J (2010) Comparison of the stability of Y-90-, Lu-177- and Ga-68- labeled human serum albumin microspheres (DOTA-HSAM). Nucl Med Biol 37(8):861-867
229. Yang DJ, Kim EE (2005) Tracer development and hybrid imaging. Eur J Nucl Med Mol Imaging 32(9):1001-1002 (Pubitemid 41339273)
230. Yang DJ, Azhdarinia A, Kim EE (2005) Tumor Specific Imaging Using Tc-99 m and Ga-68 labeled radiopharmaceuticals. Curr Med Imaging Rev 1(1):25-34
231. Yang DJ, Kim EE, Inoue T (2006) Targeted molecular imaging in oncology. Ann Nucl Med 20(1):1-11 (Pubitemid 43356305)
232. Yang BY, Jeong JM, Kim YJ, Choi JY, Lee YS, Lee DS, Chung JK, Lee MC (2010) Formulation of 68 Ga BAPEN kit for myocardial positron emission tomography imaging and biodistribution study. Nucl Med Biol 37(2):149-155
233. Yano Y, Budinger TF, Ebbe SN, Mathis CA, Singh M, Brennan KM, Moyer BR (1985) Gallium-68 lipophilic complexes for labeling platelets. J Nucl Med 26(12):1429-1437 (Pubitemid 16063026)
234. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Natl Rev Mol Cell Biol 2(2):127-137 (Pubitemid 33674041)
235. Yvert JP, Maziere B, Verhas M, Comar D (1979) Simple, fast preparation of gallium-68-labeled human-serum albumin microspheres. Eur J Nucl Med 4(2):95-99 (Pubitemid 9218284)
236. Zhang Z, Lyster DM, Webb GA, Orvig C (1992) Potential 67 Ga radiopharmaceuticals for myocardial imaging: Tris(1-aryl-3-hydroxy-2-methyl-4- pyridinonato)gallium(III) complexes. Int J Rad Appl Instrum B 19(3):327-335
237. Zhang HW, Schuhmacher J, Waser B, Wild D, Eisenhut M, Reubi JC, Maecke HR (2007) DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. Eur J Nucl Med Mol Imaging 34(8):1198-1208 (Pubitemid 47296770)
238. Zhang H, Moroz MA, Serganova I, Ku T, Huang R, Vider J, Maecke HR, Larson SM, Blasberg R, Smith-Jones PM (2010) Imaging expression of the human somatostatin receptor subtype-2 reporter gene with 68 Ga-DOTATOC. J Nucl Med: jnumed.110.079004
239. Zhernosekov KP, Filosofov DV, Baum RP, Aschoff P, Bihl H, Razbash AA, Jahn M, Jennewein M, Rosch F (2007) Processing of generator-produced 68 Ga for medical application. J Nucl Med 48(10):1741-1748